In: BHRT|BHRT 101|BHRT for Women|For Physicians|For Women|Menopause
The three types of hormones typically prescribed for bio-identical hormone replacement therapy (BHRT) are estrogens, progesterones and androgens. The precise components of each woman’s therapy need to be determined after physical examination, medical history, and laboratory testing are considered. Close monitoring is essential to ensure that appropriate dosage adjustments are made.
Estrogens:
The term “estrogen” actually refers to a group of related hormones, each with a unique profile of activity. The three principle estrogens in humans are estriol [E3], estradiol[E2], and estrone[E1]. The use of one or more of these hormones is referred to as Estrogen Replacement Therapy [ERT]. These hormones are often prescribed in combination to re-establish a normal physiologic balance.
Estriol has been shown to be clinically effective for the treatment of menopausal symptoms and problems including vaginal atrophy, dryness, vaginal infections, painful intercourse, incontinence, and recurrent urinary tract infections. Estradiol is the primary estrogen of ovarian origin and the major form of estrogen in premenopausal women. Estrone (made from the conversion of estradiol and androstenedione) is the primary estrogen in post-menopausal women.
C-reaction protein (CRP) is one of the main independent predictors of cardiovascular events. Oral post-menopausal ERT increases CRP levels by a first-pass hepatic effect. These elevated levels of CRP may be responsible for the early increased cardiovascular risk that has been reported shortly after women begin oral combined HRT using NON bio-identical synthetic hormones. However, transdermal beta-estradiol has shown no significant effect on CRP in either short-term or long-term use.
Despite studies reporting the risks associated with synthetic hormones, conjugated equine estrogens remain the frequently prescribed form of ERT. Metabolites (breakdown products) of these synthetic estrogens have been linked to the development of breast cancer.
In addition to treating menopausal symptoms, ERT has been shown to be effective in decreasing the risk of colorectal cancer, and has potential for treating patients with Multiple Sclerosis and arthritis.
Progesterone:
Natural bio-identical progesterone is commonly prescribed for perimenopausal women to counteract the condition known as “estrogen dominance.” Perimenopausal women to counteract the condition known as “estrogen dominance.” Perimenopause is the time between the onset of changes in hormonal secretions and menopause, and is characterized by fluctuating hormones. Estrogen dominance occurs when a woman produces smaller amounts of progesterone than normal relative to estrogen levels.
Jerilynn Prior, M.D., of the University of British Columbia in Vancouver, has presented evidence that progesterone can stimulate new bone formation in women with osteoporosis. This may indicate a role for progesterone use, alone or combined with estrogen which reduces bone loss, in improving Bone Mineral Density.
The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial confirmed that synthetic progestins partially negate the beneficial effects on cholesterol levels that result from taking estrogen. Natural progesterone, on the other hand, maintains the benefits of estrogen on cholesterol while minimizing the side effects associated with synthetic progestins such as medroxyprogesterone acetate.
The administration of 17 alphahydroxyprogesterone caproate or progesterone suppositories to women with high-risk pregnancies has significantly reduced the incidence of preterm birth.
Approximately one in ten new mothers from postpartum depression, or postnatal illnes (PNI). “Unfortunately, women who have had PMS are prone to develop postnatal illness, but the good news is that PNI can be prevented by receiving progesterone” immediately after delivery. Women who have had postpartum depression once have about a 68% chance of recurrence after another pregnancy, but trials of prophylactic progesterone worldwide have shown that it is possible to reduce this recurrence rate to 7%.
Mayo Clinic researchers surveyed 176 women taking natural micronized progesterone who had previously taken synthetic progestins to see if natural progesterone, when compared to synthetics, made a difference in the women’s overall quality of life, menopausal symptoms, and satisfaction on micronized progesterone compared to their previous HRT, reporting these improvements: 50% in hot flashes, 42% in depression, and 47% in anxiety. Micronized progesterone was also more effective in controlling breakthrough bleeding.
Hermsmeyer, Miyagawa and Frank of Oregon Health Sciences University and USC School of Medicine compared medroxyprogesterone acetate (MPA) with natural progesterone as the progestin in HRT and studies the corresponding effect on coronary artery vasospasm. This research showed that progesterone plus estradiol protected against vasospasm, but, MPA estradiol did not. In the past, the selection of MPA over progesterone has been based on familiarity and convenience. Based on these results, formulations of natural progesterone would appear to be the wiser choice.
Androgens, such as testosterone:
Recently, attention has turned to the addition of the androgens testosterone and dehydroepiandrosterone (DHEA) to ERT in order to alleviate recalcitrant menopausal symptoms and further protect against osteoporosis, loss of immune function, obesity, and diabetes. ERT may represent incomplete prevention hormonal treatment in postmenopausal women because it does not directly address the declines in serum testosterone associated with hysterectomies and age-related gender-independent decline in DHEA and DHEA-sulfate. Additionally, ERT may cause relative ovarian and adrenal androgen deficiency, creating a rationale for concurrent physiologic androgen replacement.
The addition of testosterone to conventional hormone therapy for postmenopausal women does not increase and may indeed reduce the hormone therapy-associated breast cancer risk, thereby returning the incidence to the normal rates observed in the general, untreated population.
Every woman is unique. Therefore, it is a sensible approach for a patient to work together with health care professionals to customize hormone replacement therapy. Bio-identical HRT can be customized in the needed strength and dosage form and administered via the most appropriate route to meet each woman’s individual needs.
If you are considering Hormone Replacement Therapy contact:
The Healthy Choice Compounding Pharmacy
6 South Greeley Ave.,
Chappaqua, NY 10514
Phone (914) 238-1700/Fax (914)238-1834
Please share your experiences with hormone replacement therapy:
The goal of SimplyBHRT is to be your resource for all BHRT questions and news. The Healthy Choice opened its doors in 1996, and we have been caring for all of our patients compounding, pharmaceutical, pain relief and holistic needs. Let our compounding expertise and holistic approach to medicine help you with any BHRT questions you may have.
3 Responses to Hormones Typically Prescribed for BHRT; explained by Phil Altman, R.Ph., Compounding Pharmacist
forex robot
February 5th, 2010 at 1:04 am
nice post. thanks.
admin
February 12th, 2010 at 9:13 am
Your’e welcome! What other information on BHRT would you like to hear about?
Peyton Rivera
May 18th, 2010 at 12:04 am
When you reach menopause, you may need some hormone replacement therapy just to stay on top shape.-’~